title: A randomized trial to compare the efficacy and safety of antiemetic treatment with ondansetron and ondansetron zydis in patients with breast cancer treated with high-dose epirubicin.
abstract: OBJECTIVE
  The objective of this study was to compare the efficacy of a disintegrating tablet of ondansetron (ODT) and the conventional tablet formulation of ondansetron (OT) in controlling nausea and vomiting in breast cancer patients.
  
  
  METHODS
  A total of 134 breast cancer patients receiving high-dose epirubicin participated in a randomized trial comparing the antiemetic efficacy and safety of an 8 mg OT given twice daily to an 8 mg orally ODT given twice daily, both for 3 days.
  
  
  RESULTS
  OT was significantly better in the complete control of emesis (72% versus 52%, p=0.020) and marginally better in the complete control of nausea (66% versus 48%, p=0.054) induced by high-dose epirubicin over days 1-3 compared to ODT. However, no differences were found in major control of emesis (0 to 2 emetic episodes, 76% versus 70%, p=0.28) over days 1-3.
  
  
  CONCLUSIONS
  OT was significantly better in the complete control of emesis and marginally better in the complete control of nausea, but not in the major control of emesis and nausea induced by high-dose epirubicin compared to ODT. ODT may be an effective alternative to OT, particularly in patients who have difficulties in swallowing a conventional tablet.
authors.affiliation: Second Department of Internal Medicine, Propaedeutic, Oncology Section, Attikon University Hospital, Athens, Greece. pectasid@otenet.gr
authors.forename: D
authors.initials: D
authors.lastname: Pectasides
authors.forename: U
authors.initials: U
authors.lastname: Dafni
authors.forename: G
authors.initials: G
authors.lastname: Aravantinos
authors.forename: E
authors.initials: E
authors.lastname: Timotheadou
authors.forename: D V
authors.initials: DV
authors.lastname: Skarlos
authors.forename: N
authors.initials: N
authors.lastname: Pavlidis
authors.forename: A
authors.initials: A
authors.lastname: Gaglia
authors.forename: H P
authors.initials: HP
authors.lastname: Kalofonos
authors.forename: G
authors.initials: G
authors.lastname: Fountzilas
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000932:Antiemetics / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols; D001943:Breast Neoplasms / Q000188:drug therapy*; D015251:Epirubicin / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008875:Middle Aged; D017294:Ondansetron / Q000008:administration & dosage*; D013607:Tablets; D014839:Vomiting / Q000139:chemically induced / Q000517:prevention & control*
chemical_list: D000932:Antiemetics; D013607:Tablets; D015251:Epirubicin; D017294:Ondansetron